Blood Test Could Match and Monitor Cancer Patients and Treatment
By LabMedica International staff writers Posted on 01 Nov 2015 |
Image: New study shows that blood testing by targeted-NGS of extracted cfDNA could help match cancer patients with the most appropriate targeted therapy and to simply and quickly monitor response to treatment (Photo courtesy of Cancer Research UK).
Researchers have found that new generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in blood plasma could help successfully pair cancer patients with the most suitable therapy and track tumor progression to assess treatment effectiveness.
Genetic monitoring of a patient’s tumor provides information on how the cancer is changing and whether it is becoming resistant to treatment. Researchers and clinicians from The Institute of Cancer Research (London, UK and The Royal Marsden Hospital (London, UK) examined genetic mutations in cfDNA extracted from 150 plasma samples from 39 patients, with late-stage cancer of known tumor mutation, who were participating in early-phase clinical trials of targeted drugs. Treatments targeted mainly the PI3K-AKT-mTOR pathway or MEK. This is the first study where a blood test has been used in this way during clinical trials of targeted drugs, showing that targeted-NGS of cfDNA has potential to simply and quickly monitor response to targeted therapy.
Tumor biopsies are generally taken only at the beginning of treatment, so information is unavailable about how tumor genetic makeup is changing in response to treatment. Blood-testing could provide real-time updates, as well as help doctors identify patients suitable for clinical trials of new drugs.
“Tumors and the gene faults that drive them are unique and constantly evolving. It’s crucial that we understand these changes so doctors can choose the best treatments for each patient,” said study leader Prof. Johann de Bono, from the Institute of Cancer Research, London and The Royal Marsden, “We need to do more research, but this approach could have a huge impact on how we make treatment decisions, also potentially making diagnosis and treatment quicker, cheaper, and less invasive.”
“Blood tests like these are the future of cancer treatment and this study proves that they can work in practice–helping us to diagnose, analyze, and monitor tumors more easily,” said Dr. Kat Arney, science information manager, Cancer Research UK (London, UK), “Thanks to research like this we’re developing new ways to shake the genetic foundations that underpin cancer and save more lives.”
The study, by Frenel et al., was published October 15, 2015, in the journal Clinical Cancer Research.
Related Links:
Institute of Cancer Research, London
The Royal Marsden Hospital
Cancer Research UK
Genetic monitoring of a patient’s tumor provides information on how the cancer is changing and whether it is becoming resistant to treatment. Researchers and clinicians from The Institute of Cancer Research (London, UK and The Royal Marsden Hospital (London, UK) examined genetic mutations in cfDNA extracted from 150 plasma samples from 39 patients, with late-stage cancer of known tumor mutation, who were participating in early-phase clinical trials of targeted drugs. Treatments targeted mainly the PI3K-AKT-mTOR pathway or MEK. This is the first study where a blood test has been used in this way during clinical trials of targeted drugs, showing that targeted-NGS of cfDNA has potential to simply and quickly monitor response to targeted therapy.
Tumor biopsies are generally taken only at the beginning of treatment, so information is unavailable about how tumor genetic makeup is changing in response to treatment. Blood-testing could provide real-time updates, as well as help doctors identify patients suitable for clinical trials of new drugs.
“Tumors and the gene faults that drive them are unique and constantly evolving. It’s crucial that we understand these changes so doctors can choose the best treatments for each patient,” said study leader Prof. Johann de Bono, from the Institute of Cancer Research, London and The Royal Marsden, “We need to do more research, but this approach could have a huge impact on how we make treatment decisions, also potentially making diagnosis and treatment quicker, cheaper, and less invasive.”
“Blood tests like these are the future of cancer treatment and this study proves that they can work in practice–helping us to diagnose, analyze, and monitor tumors more easily,” said Dr. Kat Arney, science information manager, Cancer Research UK (London, UK), “Thanks to research like this we’re developing new ways to shake the genetic foundations that underpin cancer and save more lives.”
The study, by Frenel et al., was published October 15, 2015, in the journal Clinical Cancer Research.
Related Links:
Institute of Cancer Research, London
The Royal Marsden Hospital
Cancer Research UK
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans